Literature DB >> 19366581

Development of the rubella vaccine and vaccination strategy in Japan.

Kohji Ueda1.   

Abstract

The development of the rubella vaccine and vaccination strategy in Japan was unique. Five rubella vaccines used in Japan were licensed, and the rubella vaccine program to schoolgirls was started in 1977. The measles-mumps-rubella vaccination to children which started in 1989, was terminated in 1993 due to the adverse effect of aseptic meningitis. In 1994, rubella vaccination to children, using the monovalent rubella vaccine, was restarted. Then, a new vaccination program, vaccinating twice by using the combined measles and rubella vaccine, was started in 2006. The increase in the rate of vaccination leads us to hope for the "Elimination of Rubella and Congenital Rubella Syndrome in 2012".

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366581     DOI: 10.1016/j.vaccine.2009.02.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Persistence and titer changes of rubella virus antibodies in primiparous women who had been vaccinated with strain RA 27/3 in junior high school.

Authors:  Ching-Chiang Lin; Chun-Yuh Yang; Yung-Luen Shih; Yang-Yang Huang; Tsung-Han Yang; Jin-Yuan Liang; Chu-Fen Chang; Hsiu-Shu Hsieh; Yeou-Lih Huang
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

Review 2.  Vaccine chronicle in Japan.

Authors:  Tetsuo Nakayama
Journal:  J Infect Chemother       Date:  2013-07-09       Impact factor: 2.211

3.  Assessing the Effectiveness and Cost-Benefit of Test-and-Vaccinate Policy for Supplementary Vaccination against Rubella with Limited Doses.

Authors:  Masaya M Saito; Keisuke Ejima; Ryo Kinoshita; Hiroshi Nishiura
Journal:  Int J Environ Res Public Health       Date:  2018-03-22       Impact factor: 3.390

4.  A Socio-Demographic Examination of Adults Responding to Governmental Vaccination Recommendations during the Japanese Rubella Outbreak of 2013.

Authors:  Ai Hori; Koji Wada; Derek R Smith
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.